Cells have the potential to do far more than nature originally designed them for. Constructive Bio is pioneering genome writing and genetic code reprogramming, creating entirely new classes of biomolecules with applications in therapeutics, biomaterials, and sustainable manufacturing. Their platform enables precise control over the genetic blueprint of living cells, unlocking innovations from virus-resistant biofactories to next-generation protein engineering.
We are pleased to welcome Constructive Bio to the LongeVC portfolio. Led by CEO Ola Wlodek, and prof. Jason Chin, the company builds on decades of research from the MRC Laboratory of Molecular Biology to push synthetic biology beyond its current limits.
Looking forward to supporting their journey as they develop scalable solutions for the next generation of therapeutics and bio-based materials.
Learn more about Constructive Bio here.
We are pleased to welcome Constructive Bio to the LongeVC portfolio. Led by CEO Ola Wlodek, and prof. Jason Chin, the company builds on decades of research from the MRC Laboratory of Molecular Biology to push synthetic biology beyond its current limits.
Looking forward to supporting their journey as they develop scalable solutions for the next generation of therapeutics and bio-based materials.
Learn more about Constructive Bio here.